Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marizyme, Inc., a Nevada corporation in medical technology development, executed an Assignment for the Benefit of Creditors dated April 14, 2026. The assignment transfers substantially all of Marizyme’s assets to Peter Hurwitz, including real property and fixtures, inventory, equipment, accounts receivable, bank deposits, cash, promissory notes, insurance policy cash value, and related proceeds and claims.
The assignee will administer the estate under Chapter 727 of the Florida Statutes, liquidate assets with reasonable dispatch, collect claims, and pay creditors and related administrative expenses from estate proceeds on a pro rata basis consistent with statutory priority. Any remaining funds after paying debts and liabilities in full would be returned to Marizyme.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026